Confirmatory phase III study of UCB0107 in patients with progressive supranuclear palsy
Latest Information Update: 04 Aug 2020
At a glance
- Drugs Bepranemab (Primary)
- Indications Progressive supranuclear palsy
- Focus Therapeutic Use
- 04 Aug 2020 New trial record
- 28 Jul 2020 According to an UCB media release, the company continues to develop UCB0107 in progressive supranuclear palsy (PSP), with a confirmatory phase 3 study due to commence in Q2 2021.